We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Thermo Fisher Scientific - Direct Effect Media

Abbott Diagnostics

  Gold Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App





Abbott's USD 5, 15-Minute BinaxNOW COVID-19 Ag Card Becomes First Diagnostic Test with Read-Result Test Card to Receive FDA EUA

By HospiMedica International staff writers
Posted on 28 Aug 2020
Print article
Image: Abbott Laboratories` BinaxNOW rapid Covid-19 test (Photo courtesy of Abbott Laboratories)
Image: Abbott Laboratories` BinaxNOW rapid Covid-19 test (Photo courtesy of Abbott Laboratories)
Abbott (Lake Forest, IL, USA) has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for its BinaxNOW COVID-19 Ag Card rapid test for the detection of COVID-19 infection.

BinaxNOW is highly portable (about the size of a credit card), affordable at USD 5 and provides results in 15 minutes. The test uses proven Abbott lateral flow technology, making it a reliable and familiar format for frequent mass testing through their healthcare provider. It is intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in nasal swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset. With no equipment required, the device will be an important tool to manage risk by quickly identifying infectious people who are currently infected and who should isolate themselves to help prevent the spread of the disease.

In data submitted to the FDA from a clinical study conducted by Abbott with several leading US research universities, the BinaxNOW COVID-19 Ag Card demonstrated sensitivity of 97.1% (positive percent agreement) and specificity of 98.5% (negative percent agreement) in patients suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset. The BinaxNOW COVID-19 Ag Card is the sixth test that Abbott is launching in the US to help fight the coronavirus pandemic.

Abbott will also launch a complementary mobile app for iPhone and Android devices named NAVICA. This first-of-its-kind app, available at no charge, will allow people who test negative to display a temporary digital health pass that is renewed each time a person is tested through their healthcare provider together with the date of the test result. If test results are negative, the app will display a digital health pass via a QR code, similar to an airline boarding pass. If test results are positive, people receive a message to quarantine and talk to their doctor. Organizations will be able to view and verify the information on a mobile device to facilitate entry into facilities along with hand-washing, social distancing, enhanced cleaning and mask-wearing. The app is supported by Apple and Android digital wallets and will be available from public app stores in the US.

Additionally, Abbott has entered into a deal worth USD 750 million with the US government to supply 150 million BinaxNOW COVID-19 Ag Card rapid tests for the detection of COVID-19 infection, substantially expanding the nation’s capacity for rapid testing.

"The massive scale of this test and app will allow tens of millions of people to have access to rapid and reliable testing," said Joseph Petrosino, Ph.D., professor and chairman, Molecular Virology and Microbiology, Baylor College of Medicine, whose labs have been leading efforts to provide COVID-19 testing for the college and Harris County. "With lab-based tests, you get excellent sensitivity but might have to wait days or longer to get the results. With a rapid antigen test, you get a result right away, getting infectious people off the streets and into quarantine so they don't spread the virus."

"We intentionally designed the BinaxNOW test and NAVICA app so we could offer a comprehensive testing solution to help Americans feel more confident about their health and lives," said Robert B. Ford, president and chief executive officer, Abbott. "BinaxNOW and the NAVICA app give us an affordable, easy-to-use, scalable test, and a complementary digital health tool to help us have a bit more normalcy in our daily lives."


Print article

Channels

Critical Care

view channel
Image: Triage Cardiac Panel is a rapid, POC fluorescence immunoassay used with Triage MeterPro (Photo courtesy of Quidel)

Quidel Triage Cardiac Panel Facilitates Rapid POC Diagnosis of Chest Pain Patients in ED

Chest and abdominal pain are the most common reasons that persons aged 15 years and over visit the emergency department (ED). Because both emergency and non-emergency care are provided, symptoms vary widely... Read more

Surgical Techniques

view channel
Image: A minimally invasive diagnostic biomarker strategy has proven successful in detecting early esophageal cancer (Photo courtesy of Pexels)

Minimally Invasive Device Combined With Molecular Biomarkers Detects Early Esophageal Cancer

Esophageal cancer remains the sixth-most common cause of cancer death worldwide, claiming the lives of more than half a million people annually. Esophageal squamous cell carcinoma (ESCC) comprises 80%... Read more

Patient Care

view channel
Image: Future wearable health tech could measure gases released from skin (Photo courtesy of Pexels)

Wearable Health Tech Could Measure Gases Released From Skin to Monitor Metabolic Diseases

Most research on measuring human biomarkers, which are measures of a body’s health, rely on electrical signals to sense the chemicals excreted in sweat. But sensors that rely on perspiration often require... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.